ZENNER PATRICK J
Known title: DirectorCIK: 0001139036
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
West Pharmaceutical Services noted in analyst upgrade and market rally. West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.
Transaction History
| RNAC | ▲ Buy | Grant | 2,600 | $0 | 1/2/2026 | View on chart |
| RNAC | ▲ Buy | Grant | 2,600 | $0 | 1/2/2025 | View on chart |
| RNAC | ▲ Buy | Grant | 178,000 | $0 | 1/2/2024 | View on chart |
| WST | ▼ Sell | Gift | 11,517 | $0 | 9/9/2021 | View on chart |
| WST | ▼ Sell | Gift | 310 | $0 | 5/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session
Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session. Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.